Hospital anxiety and depression scale assessment of 100 patients before and after using low vision care: A prospective study in a tertiary eye-care setting

BackgroundWhether alexithymia is a personality trait that increases the risk of major depression (MD) is still debated. In this prospective study, alexithymic levels were evaluated before, during and after a depressive episode.MethodThe alexithymic levels, the presence of MD and the severity of anxious-depressive symptoms were evaluated at intervals of about 1 month in pregnant women attending the Centers for Prenatal Care, using the Toronto Alexithymia Scale (TAS), the Primary Care Evaluation of Mental Disorders (PRIME-MD) and the Hospital Anxiety and Depression Scale (HADS).ResultsSixteen women affected by MD, 21 affected by subthreshold depression and 112 non-depressed women were included in the study. Women who developed depression, compared to non-depressed women, showed similar TAS and HADS scores during the pre-morbid phase, a significant increase in the scores during depression and a significant decrease after remission, whereas no change was observed in non-depressed women.ConclusionsOur data suggest that in pregnant women alexithymia does not represent a personality trait that increases the risk of developing a depressive episode, and they support the hypothesis that alexithymia is a state-dependent phenomenon in depressed pregnant women.

Download Full-text

Perceptions of prognosis and goal of treatment in patients with malignant gliomas and their caregivers

Neuro-Oncology Practice ◽

10.1093/nop/npaa021 ◽

2020 ◽

Vol 7 (5) ◽

pp. 490-497

Author(s):

Deborah A Forst ◽

Kit Quain ◽

Sophia L Landay ◽

Maya Anand ◽

Emilia Kaslow-Zieve ◽

...

Keyword(s):

Malignant Gliomas ◽

Depression Scale ◽

Primary Treatment ◽

Treatment Goal ◽

Anxiety And Depression ◽

Newly Diagnosed ◽

Hospital Anxiety ◽

Treatment Perceptions ◽

Multivariable Regression ◽

A Prospective Study

Abstract Background Patients with malignant gliomas have a poor prognosis. However, little is known about patients’ and caregivers’ understanding of the prognosis and the primary treatment goal. Methods We conducted a prospective study in patients with newly diagnosed malignant gliomas (N = 72) and their caregivers (N = 55). At 12 weeks after diagnosis, we administered the Prognosis and Treatment Perceptions Questionnaire to assess understanding of prognosis and the Hospital Anxiety and Depression Scale to evaluate mood. We used multivariable regression analyses to explore associations between prognostic understanding and mood and McNemar tests to compare prognostic perceptions among patient-caregiver dyads (N = 48). Results A total of 87.1% (61/70) of patients and 79.6% (43/54) of caregivers reported that it was “very” or “extremely” important to know about the patient’s prognosis. The majority of patients (72.7%, [48/66]) reported that their cancer was curable. Patients who reported that their illness was incurable had greater depressive symptoms (B = 3.01, 95% CI, 0.89-5.14, P = .01). There was no association between caregivers’ prognostic understanding and mood. Among patient-caregiver dyads, patients were more likely than caregivers to report that their primary treatment goal was cure (43.8% [21/48] vs 25.0% [12/48], P = .04) and that the oncologist’s primary goal was cure (29.2% [14/48] vs 8.3% [4/48], P = .02). Conclusions Patients with malignant gliomas frequently hold inaccurate perceptions of the prognosis and treatment goal. Although caregivers more often report an accurate assessment of these metrics, many still report an overly optimistic perception of prognosis. Interventions are needed to enhance prognostic communication and to help patients cope with the associated distress.

Download Full-text

Psychological Effects of Foldable Capsular Vitreous Body Implantation in Patients with Impending Eye Atrophy

10.21203/rs.3.rs-327015/v1 ◽

2021 ◽

Author(s):

Zheyi Shao ◽

Chao Huang ◽

Ying Zhang ◽

Shanshan Li ◽

Donglin Wang ◽

...

Keyword(s):

Mental Health ◽

Interpersonal Communication ◽

Ocular Trauma ◽

Depression Scale ◽

Vitreous Body ◽

Interpersonal Sensitivity ◽

Anxiety And Depression ◽

Hospital Anxiety ◽

Before And After ◽

Baseline Demographic

Abstract Purpose: To investigate whether the FCVB could help improve the mental health of patients with impending eye atrophy. Methods: Fifty-five patients who underwent FCVB implantation from 2017 to 2019 were screened to take part in this retrospective study. The researchers used independent third parties to distribute questionnaires, including the Hospital Anxiety and Depression Scale and the interpersonal sensitivity part of the Symptom Checklist 90 (SCL-90) scale to score the patients' depression, anxiety, and interpersonal sensitivity before and after surgery. Finally, 52 responses were collected.Results: After FCVB implantation, patients had significantly better mental health and less depression, anxiety, and interpersonal sensitivity levels. Before FCVB implantation, 44.23% of patients with ocular trauma and retinal detachment were depressed, 48.08% were anxious, and 19.23% were sensitive to interpersonal communication. After FCVB implantation, 17.31% were depressed, 15.38% were anxious, and 9.62% were sensitive to interpersonal communication. However, baseline demographic and clinical data, such as age, gender, occupation, finance, pre-FCVB-implantation vision, number of surgeries before FCVB implantation, postoperative period length, and surgical satisfaction, had no significant effects on psychological scores of mental health before and after surgery (P> 0.05). Conclusion: Mental health (depression, anxiety, and interpersonal sensitivity) significantly improved in patients after FCVB implantation.

Download Full-text

Validity Study of the Hospital Anxiety and Depression Scale Among a Group of Saudi Patients

The British Journal of Psychiatry ◽

10.1192/bjp.151.5.687 ◽

1987 ◽

Vol 151 (5) ◽

pp. 687-688 ◽

Cited By ~ 47

Author(s):

O.E.F.A. El-Rufaie ◽

Gamil Absood

Keyword(s):

Care Setting ◽

Depression Scale ◽

Anxiety And Depression ◽

Arabic Version ◽

Hospital Anxiety ◽

Clinical Evaluations ◽

Reliable Instrument ◽

Scale Scores ◽

Had Scale ◽

Saudi Patients

The Arabic version of the HAD scale was validated in a sample of 50 Saudi patients. The scale scores were assessed against the principal author's clinical evaluations. Spearman correlations of all items of the scale, except for one, were statistically significant. The non-significance of one item was probably related to the way it was translated into Arabic. The study furnished evidence that the Arabic version was a reliable instrument for detecting states of anxiety and depression in Saudi patients in a primary health care setting.

Download Full-text

Course of distress, anxiety, and depression in hematological cancer patients: Association between gender and grade of neoplasm

Palliative & Supportive Care ◽

10.1017/s1478951513000849 ◽

2013 ◽

Vol 13 (2) ◽

pp. 115-123 ◽

Cited By ~ 27

Author(s):

Cristiane Decat Bergerot ◽

Karen Lynn Clark ◽

Alexandre Nonino ◽

Sarah Waliany ◽

Marco Murilo Buso ◽

...

Keyword(s):

Significant Interaction ◽

Depression Scale ◽

Anxiety And Depression ◽

Hospital Anxiety ◽

Hematological Cancer ◽

Physical Problems ◽

Male Patients ◽

A Prospective Study ◽

The Impact ◽

Over Time

AbstractObjective:The aim of our study was to explore the impact of gender and hematological cancer grade on distress, anxiety, and depression in patients receiving chemotherapy.Methods:A prospective study was done in a cohort of 104 patients with hematological cancer. We employed the (1) Distress Thermometer (DT) and the Problem List (PL) and (2) the Hospital Anxiety and Depression Scale (HADS) for assessments at baseline (T1), the halfway timepoint (T2), and completion of chemotherapy (T3).Results:The proportion of patients experiencing significant distress (DT ≥ 4) decreased from the first to the last timepoint; the proportion experiencing anxiety and depression (as assessed by HADS) also decreased. Specifically, 50% of participants reported significant distress levels, 47.1% anxiety, and 26% depression at T1. At T2, the proportion of patients experiencing distress was reduced by 60.8%, by 76% for anxiety, and by 48.5% for depression; at T3, the reduction was close to 80% for all assessments compared with T1. Emotional and physical problems were most commonly reported. Significant reductions were discovered for distress and problem-related distress levels over time, and a significant interaction was found between gender and practical and physical problems (p < 0.05).Significance of results:Our findings suggest that female patients reported more distress, anxiety, and depression than male patients. Gender differences were related to problem-related distress but not to grade of neoplasm. We observed that, over the course of chemotherapy, the distress levels of patients with hematological cancer decrease over time.

Download Full-text

Improving of psychological status and inflammatory biomarkers during omalizumab for chronic spontaneous urticaria

Future Science OA ◽

10.2144/fsoa-2020-0087 ◽

2020 ◽

pp. FSO618

Author(s):

Laura Diluvio ◽

Arianna Piccolo ◽

Francesco Marasco ◽

Laura Vollono ◽

Caterina Lanna ◽

...

Keyword(s):

Healthy Subjects ◽

Depression Scale ◽

Chronic Spontaneous Urticaria ◽

Psychological Status ◽

Anxiety And Depression ◽

Depression And Anxiety ◽

Hospital Anxiety ◽

Erythrocyte Sedimentation ◽

Before And After ◽

Mental Comorbidities

Background: Depression and anxiety are the most common psychiatric comorbidities in chronic spontaneous urticaria (CSU). Omalizumab is a monoclonal antibody approved for CSU treatment. We evaluated the prevalence of anxiety and depression in CSU patients before and after treatment with omalizumab. Materials & methods: A total of 30 patients were enrolled in the study: 15 patients affected by CSU and treated with omalizumab and the other 15 healthy subjects did not receive any systemic therapy. All patients were evaluated using Hospital Anxiety and Depression Scale, CRP and erythrocyte sedimentation rate, at baseline and after 6 months. Results: The omalizumab group after 6 months of therapy had a decrease of all the scores and biomarkers. Conclusion: Omalizumab allowed an improvement of urticaria and mental comorbidities.

Download Full-text

Mental Health State of Low Vision Patients using the Hospital Anxiety and Depression Scale and The Depression, Anxiety and Stress Scale

Medicine & Health ◽

10.17576/mh.2020.1501.18 ◽

2020 ◽

Vol 15 (1) ◽

pp. 198-207

Author(s):

Mohd Harimi Abd Rahman ◽

Keyword(s):

Mental Health ◽

Low Vision ◽

Depression Scale ◽

Anxiety And Depression ◽

Health State ◽

Hospital Anxiety ◽

Stress Scale

Download Full-text

Do Anxiety and Depression Predict Persistent Physical Symptoms After a Severe COVID-19 Episode? A Prospective Study

Frontiers in Psychiatry ◽

10.3389/fpsyt.2021.757685 ◽

2021 ◽

Vol 12 ◽

Author(s):

Hugo Bottemanne ◽

Clément Gouraud ◽

Jean-Sébastien Hulot ◽

Anne Blanchard ◽

Brigitte Ranque ◽

...

Keyword(s):

Prospective Study ◽

Acute Infection ◽

Depression Scale ◽

Physical Symptom ◽

Physical Symptoms ◽

Anxiety And Depression ◽

Increased Risk ◽

A Prospective Study ◽

Anxiety Depression

Background: Persistent physical symptoms are common after a coronavirus disease 2019 (COVID-19) episode, but their pathophysiological mechanisms remain poorly understood. In this study, we aimed to explore the association between anxiety and depression at 1-month after acute infection and the presence of fatigue, dyspnea, and pain complaints at 3-month follow-up.Methods: We conducted a prospective study in patients previously hospitalized for COVID-19 followed up for 3 months. The Hospital Anxiety and Depression Scale (HAD-S) was administered by physicians at 1-month follow-up, and the presence of fatigue, dyspnea, and pain complaints was assessed at both 1 month and 3 months. Multivariable logistic regressions explored the association between anxiety and depression subscores and the persistence of each of the physical symptom at 3 months.Results: A total of 84 patients were included in this study (Median age: 60 years, interquartile range: 50.5–67.5 years, 23 women). We did not find any significant interaction between anxiety and the presence of fatigue, dyspnea, or pain complaints at 1 month in predicting the persistence of these symptoms at 3 months (all p ≥ 0.36). In contrast, depression significantly interacted with the presence of pain at 1 month in predicting the persistence of pain at 3 months (OR: 1.60, 95% CI: 1.02–2.51, p = 0.039), with a similar trend for dyspnea (OR: 1.51, 95% CI: 0.99–2.28, p = 0.052).Discussion and Conclusion: Contrary to anxiety, depression after an acute COVID-19 episode may be associated with and increased risk of some persistent physical symptoms, including pain and dyspnea.

Download Full-text

Anxiety and depression are negatively correlated with art success: prospective study using hospital anxiety and depression scale (HADS)

Fertility and Sterility ◽

10.1016/j.fertnstert.2011.07.599 ◽

2011 ◽

Vol 96 (3) ◽

pp. S153

Author(s):

H. Matsubayashi ◽

T. Sakai ◽

A. Tsukamoto ◽

A. Satoh ◽

Y. Takahashi ◽

...

Keyword(s):

Prospective Study ◽

Depression Scale ◽

Anxiety And Depression ◽

Hospital Anxiety

Download Full-text

The hidden burden of anxiety and depression in ovarian cancer: A prospective study from diagnosis.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.7_suppl.155 ◽

2018 ◽

Vol 36 (7_suppl) ◽

pp. 155-155

Author(s):

Penelope M Webb ◽

Vanessa Beesley ◽

Anna deFazio ◽

Andreas Obermair ◽

Peter T. Grant ◽

...

Keyword(s):

Ovarian Cancer ◽

Prospective Study ◽

Depression Scale ◽

Cancer Prognosis ◽

Anxiety And Depression ◽

Prior History ◽

Persistent Symptoms ◽

A Prospective Study ◽

Time Point

155 Background: Women with ovarian cancer (OC) report high rates of anxiety (A) and depression (D), but most studies have used a cross-sectional design at a single time-point, not considered prior history and not included affected women who are symptom-free due to medication. Our goals were to quantify (i) the total burden of A and D among women with newly diagnosed OC; the proportions who (ii) experience symptoms only after their OC diagnosis and (iii) with persistent symptoms; and (iv) use of appropriate medication/services by those affected. Methods: The OPAL (Ovarian Cancer Prognosis & Lifestyle) Study is a prospective study of Australian women diagnosed with OC from 2012-15 who agreed to complete questionnaires at baseline, 3, 6, 9, 12, 24, 36 & 48 months after diagnosis. At baseline, they were asked if they had ever been diagnosed with A or D and if they took medication for this in the year before their OC diagnosis. At follow-up they completed the Hospital Anxiety and Depression Scale (HADS) and were asked about current medication use. Results: Of 893 women with data for ≥1 time point, 216 (24%) reported clinical levels (HADS > 10) of anxiety (18%) and/or depression (15%) on at least one occasion during the first 3 years after diagnosis, with another 157 (18%) reporting use of anxiolytic or antidepressant medications. A further 167 (19%) reported subclinical (HADS 8-10) A or D. Of those with clinical levels of A/D and/or taking medication, 225 (60%) reported this at ≥3 time-points, 216 (58%) reported no prior history of A or D, and 271 (73%) reported no use of anxiolytic/antidepressant medication in the year before diagnosis. When women reported clinical levels of A or D, only 45% reported taking medication (37%) and/or seeing a psychiatrist or psychologist (19%). Conclusions: More than 40% of women with OC experienced clinical levels of A or D during treatment or the first 3 years of follow-up, for 25% this persisted. For 24% this was their first experience of distress and > 50% of those affected did not receive appropriate medication or psychological support. The hidden burden of anxiety and depression in this population is much greater than previously reported but is amenable to effective intervention if recognized.

Download Full-text